Articles published by Abiomed, Inc.

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

December 21, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

First Patients in the World Treated with Impella RP Flex with SmartAssist

December 05, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

November 01, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

October 31, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare

October 26, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

October 24, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

October 20, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

October 17, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

October 13, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

October 13, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

September 20, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

September 19, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

September 17, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

September 16, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

September 13, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

August 04, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification

July 14, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

June 14, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

May 31, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

April 28, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

April 08, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

First Patient in Japan Treated with Impella 5.5 with SmartAssist

April 06, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French

March 21, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

February 08, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

February 03, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification

January 14, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

January 12, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

January 10, 2022

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference

December 29, 2021

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Abiomed to Present at Upcoming Investor Conferences

November 18, 2021

From Abiomed, Inc.

Via Business Wire

Tickers ABMD

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.